| Price | 1,960.50p on 07-08-2026 at 18:35:07 |
|---|---|
| Change | 24.00p 1.24% |
| Buy | 1,957.50p |
| Sell | 1,956.50p |
| Last Trade: | Unknown 3,524.00 at 1,960.50p |
| Day's Volume: | 4,447,376 |
| Last Close: | 1,960.50p |
| Open: | 1,931.00p |
| ISIN: | GB00BN7SWP63 |
| Day's Range | 1,931.00p - 1,970.50p |
| 52wk Range: | 1,395.50p - 2,282.00p |
| Market Capitalisation: | £78.53b |
| VWAP: | 1,956.57375p |
| Shares in Issue: | 4.01b |
Glaxosmithkline (GSK) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 3,524 | 1,960.50p | OTC Trade |
17:46:57 - 07-Aug-26 |
| Buy* | 689 | 1,960.50p | Automatic Execution |
16:36:11 - 07-Aug-26 |
| Buy* | 863 | 1,960.50p | Automatic Execution |
16:36:11 - 07-Aug-26 |
| Buy* | 937 | 1,960.50p | Automatic Execution |
16:36:11 - 07-Aug-26 |
| Buy* | 751 | 1,960.50p | Automatic Execution |
16:36:11 - 07-Aug-26 |
| Buy* | 2,042 | 1,960.50p | Automatic Execution |
16:36:11 - 07-Aug-26 |
| Buy* | 401 | 1,960.50p | Automatic Execution |
16:36:11 - 07-Aug-26 |
| Buy* | 3,799 | 1,960.50p | SI Trade |
16:35:07 - 07-Aug-26 |
| Buy* | 19,944 | 1,960.50p | SI Trade |
16:35:07 - 07-Aug-26 |
| Buy* | 1,479,590 | 1,960.50p | Suspected BUY Trade |
16:35:07 - 07-Aug-26 |
Glaxosmithkline (GSK) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 3rd Aug 2026 3:00 pm | RNS | Total Voting Rights |
| 30th Jul 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 28th Jul 2026 12:05 pm | RNS | New GSK flagship R&D centre in Cambridge |
| 28th Jul 2026 12:00 pm | RNS | 2nd Quarter Results |
| 28th Jul 2026 11:06 am | RNS | Hansoh positive 2nd Phase III results for Riz-Rez |
| 24th Jul 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 24th Jul 2026 3:00 pm | RNS | Admission to Trading |
| 22nd Jul 2026 5:22 pm | RNS | Jideytro approved in US for certain lung cancers |
| 20th Jul 2026 7:00 am | RNS | Bexsero 1-dose booster EMA file acceptance |
| 17th Jul 2026 12:00 pm | RNS | Audit tender conclusion |